Emcure Pharmaceuticals IPO Review: Is It Worth Your Investment? | Emcure Pharma IPO | Namita Thapar

Emcure Pharmaceuticals IPO Review: Is It Worth Your Investment? | Emcure Pharma IPO | Namita Thapar

Emcure Pharmaceuticals IPO (Emcure Pharma IPO) opens for subscription on July 3, 2024 and closes on July 5, 2024. Is Emcure Pharma IPO worth your investment? In this Emcure Pharmaceuticals IPO Review video we will discuss points like financial performance, product portfolio, brand reach, valuation and more. Subscribe to us for more videos like Emcure Pharma IPO Review. Namita Thapar

About Emcure Pharmaceuticals Limited:

Emcure Pharmaceuticals, a leading Indian pharmaceutical company founded in 1981, is dedicated to making effective medicine accessible for a healthier world. They achieve this through a vertically integrated approach, developing, manufacturing, and marketing a wide range of pharmaceuticals across various therapeutic areas. From gynecology and cardiology to oncology and HIV/AIDS antivirals, Emcure boasts a robust product portfolio with a strong focus on research and development. This commitment to innovation positions them as a major player in the Indian pharmaceutical landscape, with their reach extending to over 70 countries globally. Namita Thapar will gain around ₹127 crore through the IPO of Emcure Pharmaceuticals which will kick off this week. Namita Thapar is one of the sharks on Shark Tank India.

More Emcure Pharmaceuticals IPO Details:

Emcure Pharma IPO price band is set at ₹960 to ₹1008 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is ₹14,112. The minimum lot size investment for sNII is 15 lots (210 shares), amounting to ₹211,680, and for bNII, it is 71 lots (994 shares), amounting to ₹1,001,952.

Contact us at [phone] via Whatsapp/Normal call

#planify #EmcurePharmaceuticalsipo #EmcurePharmaIPO #iporeview #ipoalert

[kanishgupta]

Bt the profit margin reduced every year what about it